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Abstract
Background: The aim of this study was to identify critical genes involved in non-small cell lung cancer (NSCLC)
pathogenesis that may lead to a more complete understanding of this disease and identify novel molecular targets
for use in the development of more effective therapies.
Methods: Both transcriptional and genomic profiling were performed on 69 resected NSCLC specimens and results
correlated with mutational analyses and clinical data to identify genetic alterations associated with groups of
interest.
Results: Combined analyses identified specific patterns of genetic alteration associated with adenocarcinoma vs.
squamous differentiation; KRAS mutation; TP53 mutation, metastatic potential and disease recurrence and survival.
Amplification of 3q was associated with mutations in TP53 in adenocarcinoma. A prognostic signature for disease
recurrence, reflecting KRAS pathway activation, was validated in an independent test set.
Conclusions: These results may provide the first steps in identifying new predictive biomarkers and targets for
novel therapies, thus improving outcomes for patients with this deadly disease.
Background
Non-small cell lung cancer (NSCLC) is the commonest
cause of cancer death in Western communities. Current
treatments offer the potential of cure only to the small
number of patients who present with early stage NSCLC,
whilst outcomes for those with advanced disease remain
poor. Recent advances including adjuvant chemotherapy
and targeted biological therapies have lead to modest
improvements in survival for small subgroups of patients.
Clearly new treatment approaches are required to substan-
tially improve outcome. As has been the case for other
tumour types, molecular profiling techniques have the
potential to provide benefit through improved understand-
ing of disease pathogenesis, identification of subgroups in
whom current therapies are most likely to be effective and
in the development of novel therapies.
Genetic heterogeneity is a feature of NSCLC, with vary-
ing combinations of multiple molecular alterations contri-
buting to tumour development [1]. A key challenge for
high-throughput molecular profiling techniques is to dis-
tinguish between genes whose expression is altered
directly by heritable changes in gene function and those
where changes are an inevitable down-stream conse-
quence of primary changes to genes directly involved in
disease pathogenesis. Correlation of transcriptional and
genomic data allows more focussed analysis of the large
number of genetic alterations identified by molecular pro-
filing. This study incorporates the results of both tran-
scriptional and genomic profiling for clinically relevant
subgroups of NSCLC to identify genes of potential predic-
tive or pathogenic importance in this deadly disease.
Methods
Samples
After obtaining institutional ethics approval, patients with
stage I-IIIA NSCLC seen by the St Vincent’sH o s p i t a l
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2006 and planned for curative resection were invited to
participate. Exclusion criteria included age <18 years,
administration of neoadjuvant chemotherapy, and inability
to provide informed consent. Integrated demographic,
radiological, pathological and outcome data was collected
for all consenting patients.
In addition, a small number of samples collected ear-
lier and stored in the Peter MacCallum (PeterMac) tis-
sue bank were utilised after approval by the PeterMac
Tissue Management Committee.
Microarray analyses
Samples of tumour (≥1c m
3) were selected from fresh
specimens, and then stored whole at -180°C. Only those
specimens containing >75% tumour cells and <25%
necrosis were used in molecular studies. Both RNA and
DNA were isolated from each sample for analysis using
established protocols (see additional files 1 and 2). Tran-
scriptional profiling was performed using 10,500 ele-
ment cDNA microarrays (PeterMac, Melbourne,
Australia) [2]. Genomic profiling using 2400 element
bacterial artificial chromosome (BAC) arrays was com-
pleted at the University of San Francisco, California,
USA [3]. Detailed description of transcriptional and
genomic profiling is included in additional files 3 and 4.
Mutation analyses
All samples were tested for TP53 mutations and all ade-
nocarcinoma (AC) and large cell carcinoma (LCC) sam-
ples were screened for KRAS mutations using high
resolution melting analysis [4,5] with or without DNA
sequencing.
Bioinformatic analyses
The effect of histology, presence or absence of KRAS or
TP53 mutation, tumour size and metastasis status, recur-
r e n c ew i t h i n1 2m o n t h so fs u r g e r ya n ds u r v i v a lo ng e n e
expression was explored. After removing control genes,
analysis was conducted in CRAN, R Bioconductor using
the LIMMA [6,7] package to generate detailed lists of gene
expression differences with significance p values between
each subgroup of interest. To account for multiple testing,
p values of <0.005 were considered statistically significant.
Gene lists were then interrogated using publicly available
programs (Intelligent Systems and Bioinformatics Labora-
tory, Wayne State University, Detroit, MI, USA, http://vor-
tex.cs.wayne.edu/projects.htm) to identify gene ontology
and molecular pathway patterns.
Changes in the normalized and smoothed genomic
data [8] were assigned stepwise copy change levels from
-2 to 3 (-2 = homozygous loss, -1 = heterozygous loss, 1
= single copy gain, 2 = gain of two copies, 3 = high-
level gain, 0 = normal copy number). Using these
standardised copy number values, it was possible to
make comparisons of the frequency of each level of
copy change at each BAC location for specific groups of
interest.
To compare our data with that of other groups of
patients with early stage NSCLC, we performed compar-
isons with publicly available external data sets obtained
via the NCBI Gene Expression Omnibus (GEO) website.
Different platforms were reconciled using HUGO
approved gene symbols, and extracted gene expression
data were log2 transformed, centred and scaled across
samples in order to emphasise relative expressions as
opposed to absolute values.
Integration of transcriptional and genomic profiles
Integration of transcriptional and genomic datasets was
performed by investigating levels of expression for genes
located in regions of copy number variation between
groups of interest. Genes whose differences in expression
varied in the same direction as differences in copy num-
ber between two groups (e.g. relative over-expression of
genes in a region of increased copy number) were viewed
as genes of interest.
Results
Molecular and clinical data was available for 69 patients
who underwent surgery for NSCLC between May 1999
and July 2006. Demographic and pathologic data are
included in table 1. Median follow-up for surviving
patients exceeds 35 months. After a median follow-up
of 36 months (1 - 80) for all patients, 28/68 patients
developed recurrent disease, and 23/68 patients died of
NSCLC (one patient with disseminated disease at diag-
nosis excluded from analysis). Comparable to other ser-
ies of early stage NSCLC [9], five year overall survival
rates approximated 55%.
Genomic Analysis
Aneuploidy
All samples demonstrated significant chromosomal
instability with an average of 43.6 chromosomal break-
points per sample (definedb yac h a n g ei nt h es t e p w i s e
copy number along a chromosome), with over 100 and
150 regions of high-level gain (+3) and loss (-3) respec-
tively. There was also a very high rate of low-level geno-
mic alteration (both gains and losses). On average, over
10 whole arm losses or duplications were seen per sam-
ple, with a rate of isochromosome formation of 1.6 per
genome (duplication of one arm with loss of the oppos-
ing arm of the same chromosome). These results are
c o n s i s t e n tw i t ht h eh i g h l yd i s o r d e r e dn a t u r eo fl u n g
cancer genomes. Comparisons between clinical sub-
groups of interest revealed remarkably similar degrees of
aneuploidy and chromosomal disorder in almost all
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Page 2 of 11groups (Table 2). Specifically, neither prognosis, degree
of histologic differentiation, K-Ras or TP53 status was
associated with evidence of greater aneuploidy.
Histotype comparisons
Charts documenting the averaged standardised copy
numbers at each BAC location were generated to enable
visual comparisons of genomic profiles between AC (23)
and SCC (17) (figure 1). Regions of shared change
(amplification of 5p15.33-p13.13, loss of 3p26.3-p13)
and several regions of difference (SCC: gains at 3q12.1-
q28 and 12p13.33-p12.1, losses of chromosome 4
(4pter-4qter); AC: gains of 6p25.1-p21.31, losses of
6q13-27, and a greater magnitude of change in several
regions of shared loss (9p, 13q, 17p, 18q, 19p, 19q and
22q) or gain (7p, 7q, 8q)) were identified. These findings
are consistent with previous studies [9-16].
Associations with mutation status in TP53, KRAS and EGFR
pathways
Clinical data demonstrated a trend to greater rate of TP53
mutation in SCC than AC (TP53 mutation in 9/12 (75%)
SCC and 9/18 (50%) AC, p = 0.083). Amplification of 3q
Table 1 Demographic and pathologic details for 69
NSCLC patients
Variable (number of patients
assessed)
Number Percentage (95%
CI)
Gender (69)
Male 42 61 (49-72)
Female 27 39 (28-51)
Age at definitive treatment (years)
(69)
Median (range) 70 (29 - 85)
Histology (69)
AC 30 43 (32-55)
SCC 23 33 (23-45)
LCC 16 23 (14-34)
Smoking status (69)
Never 16 23 (14-34)
Current/Ex 53 77 (66-86)
Stage (69)
IA 16 23 (14-34)
IB 26 38 (27-49)
IIA 3 4 (1-11)
IIB 7 10 (5-19)
IIIA 8 12 (6-20)
IIIB 3 4 (1-11)
IV 5* 12 (6-20)
Unknown 1# 1 (0-7)
Primary tumour size (mm) (69)
0 - 20 23 33 (23-45)
21 - 30 10 15 (8-24)
31 - 50 22 32 (22-43)
51 - 70 5 7 (3 - 16)
>70 7 10 (5 - 20)
Unknown 2^ 3 (0-9)
T < 40 mm, N1 &/or M1 (69) 13 19 (11-29)
T > 40 mm, N0M0 (69) 11 16 (9-26)
T > 70 mm, N0M0 (69) 4 6 (2-13)
K-Ras mutation (46)** 10 21 (11-34)
EGFR mutation (46)** 5 11 (4-22)
P53 mutation (69) 26 +/- 17
Definite 26 38 (27-49)
Possible 17 25 (16-36)
Recurrence (68)+ 28 41 (30-53)
Death from NSCLC (68)+ 23 34 (23-45)
Time from surgery to death (months)
(23)
Median (range) 19 (7 - 73)
AC = adenocarcinoma; LCC = large cell carcinoma; SCC = squamous cell
carcinoma.
*3 patients had solitary cerebral metastases resected at diagnosis, 1 patient
had 2 separate lung lesions (unclear if synchronous primary lesions or
pulmonary metastasis), 1 patient had disseminated disease.
# Stage unable to be determined in 1 patient after wedge resection without
nodal dissection.
^ Tumour size unable to be assessed in 1 patient who underwent incomplete
tumour resection after combined chemoradiation, and one who had
incomplete resection of an obstructing stage IIIA tumour followed by
definitive radiotherapy.
** Only AC and LCC samples were tested for mutations of K-Ras and EGFR.
+One patient with disseminated disease at diagnosis excluded from
recurrence and survival analysis.
Table 2 Comparisons of average number of breakpoints
for NSCLC subgroups
Subgroup Ave. No.
Breakpoints
Ratio of comparison (p value)
Histotype
AC 45.7 ACC:SCC = 1.1 (1.0)
SCC 43.1
LCC 39.5
Gender
Male (M) 44.9 M:F = 1.1 (1.0)
Female (F) 41.2
Smoking
Smokers (S) 44.5 S:N = 1.1 (1.0)
Never smokers (N) 41.1
Recurrence
Recurrent (R) 44.7 R:NR = 1.0 (1.0)
Non-recurrent (NR) 43.3
Survival
Non-survivors (NS) 46.5 NS:S = 1.1 (0.9)
Survivors (S) 42.8
Metastasis
Metastatic (M) 40.0 M:NM = 0.9 (0.9)
Non-metastatic (NM) 46.8
EGFR status
Mutant (m) 38.6 m:wt = 0.9 (0.9)
Wild-type (wt) 44.6
K-Ras status
Mutant (m) 42.3 m:wt = 1.0 (1.0)
Wild-type (wt) 43.9
p53 status
Mutant (m) 46.8 m:wt = 1.1 (0.9)
Wild-type (wt) 40.8
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0.004). When analysing all samples, no relationship was
found between 3q amplification and TP53 mutation (p =
0.99). However, when analysing SCC and AC separately, a
statistically significant relationship between TP53 muta-
tion and 3q amplification was detected in AC samples,
with amplification of 3q being significantly more common
in TP53 mutant cancers (1/8 and 4/10 samples with 3q
amplification in TP53 wild-type (wt) and mutant AC
groups respectively, p = 0.027). Both TP53 mutant and wt
samples more frequently demonstrated copy number loss
at the TP53 locus (17p13) than gain (11/18 and 9/12 sam-
ples in TP53 mutant and wt groups respectively).
Adenocarcinomas were screened for EGFR and KRAS
mutations. Small numbers of EGFR mutant tumours
limited detailed analysis. Good quality genomic profiles
were available for only 5 tumours with EGFR mutation
and no significant differences were seen between the
profiles of EGFR mutant and non-mutant tumours.
G e n o m i cp r o f i l e sw e r ea v a i l a b l ef o r8KRAS mutant
tumours, 31 wt and 16 tumours with unknown KRAS
mutation status (untested SCC samples). In averaged
copy number charts, KRAS mutant tumours showed a
predilection for losses of 1p36.32-p13.2, 6q11.1-q27,
11p13-11q13.2 and 11q21-12p13.1 and gains of 1q21.1-
q43 (Figure 2).
Associations with metastasis, tumour recurrence and
NSCLC-specific survival
To investigate the notion of inherent metastatic poten-
tial, molecular profiles of large (>4 cm) non-metastatic
tumours and small (<2 cm) metastatic (nodal or distant)
tumours were compared. Genomic profiles of 3 ‘meta-
static’ and 8 ‘non-metastatic’ tumours revealed some dif-
ferences in the magnitude of copy number changes,
without regions of clear difference between the two
groups. There was no correlation between genomic
changes and tumour recurrence or survival. There were
differences in the magnitude of gene copy number
changes at 7p, 8q, 9p, 15q and 17p in recurrent com-
pared to non-recurrent tumours. Contained within these
regions are the MYC oncogene (8q), as well as TP53
(17p), and the CDKN2A locus (containing p14(ARF) and
p16 tumour suppressor genes (9p) (TSG’s)).
Transcriptional Analysis
Histotype comparisons
Ranking the genes by moderated t-statistics and selecting
a p value cut-off of <0.005, 310 genes with differential
13 5 7 9 11 13 15 17 19 21
Figure 1 Plot of average standardised copy number at each BAC for AC and SCC samples. X axis: BAC location along genome. Y axis:
average standardised copy number.
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Page 4 of 11expression between 16 SCC and 25 AC samples were
identified, representing the biological processes of cell
adhesion, epidermis development, keratinisation and ker-
atinocyte differentiation. A significant proportion of
these genes had roles in antigen processing and presenta-
tion, and the phosphatidylinositol signalling pathway.
Thirty of 310 genes in the differentiating gene list were
located on chromosome 3 (p = 0.0098), implicating geno-
mic changes at this locus in determining NSCLC pheno-
type. This is consistent with the genomic data, which
indicates gain of 3q is associated with SCC histology.
Associations with mutation status in TP53, K-Ras and EGFR
pathways
Expression levels of 67 genes differed significantly
between TP53 mutant (17) and wt (21) tumours. Many
of the biological functions represented by these genes
were also strongly represented by the genes differentially
expressed between AC and SCC. In addition, 20/67 dis-
criminating genes were also included in the gene list dif-
ferentiating SCC from AC. Hierarchical clustering based
on the expression of these 67 differentially expressed
genes not only segregated TP53 mutant from wild-type
tumours, but also resulted in clustering of SCC samples
with the TP53 mutant tumours. Our results suggest that
the gene expression signature observed for TP53 mutant
tumours may be at least in part related to SCC histology
rather than TP53 biology.
Transcriptional profiles of AC and LCC tumours with
(8) and without (31) KRAS mutation were compared.
Biological processes represented by 108 differentiating
genes included cell growth, second-messenger mediated
signalling, chromosome organisation and biogenesis, and
gene regulation (mediated via histones and their effects
on biosynthesis and nucleosome assembly) (table 3).
These findings are consistent with other published stu-
dies linking KRAS mutation to increased translation of
cancer related proteins, and chromosome instability
[17,18]. The low frequency of EGFR mutant cancers
precluded statistically meaningful analysis of transcrip-
tional data according to EGFR genotype.
Associations with metastasis, tumour recurrence and
NSCLC-specific survival
Transcriptional profiles identified 39 genes that differen-
tiated between 19 ‘metastatic’ and 35 ‘non-metastatic’
tumours, with molecular pathways involved in protein
translation most strongly represented (MRPL33, RPL12,
RPL27A, RPS5, RPS9). Comparison of expression pro-
files of 14 tumours recurring within 12 months of sur-
gery to remaining samples identified 60 genes with
differential expression between the two groups, with a
1  3  5  7  9  11  13  15  17  19  21 
Figure 2 Chart of average standardised copy number at each BAC location for K-Ras mutant vs. wild-type tumours. X axis: BAC location
along genome. Y axis: average standardised copy number.
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ontological and single gene analyses. Included in the
differentiating gene list were MAPK1, DUSP11 and
DUSP13, PTPN11,a n dPIK3CB,a l lh a v i n gr o l e si n
signal transduction and the MAPK pathway. The phos-
phatidylinositol signalling pathway was also significantly
over-represented in ontology analysis.
Expression levels of only 38 genes differed significantly
between deceased and surviving patients. 18 of these
genes were shared with gene lists of recurrent vs. non-
recurrent tumours. Few biological processes were repre-
sented by more than one gene, and clear patterns of
gene ontology were not apparent.
Correlation with External Data Sets
Comparison of our differential gene list for recurrence with
the discriminating gene list for survival in GSE11117 (tran-
scriptional and survival data for 41 NSCLC samples, using
Novachip Human 34.5k microarray interrogating ~34,500
transcripts for each sample; http://www.ncbi.nlm.nih.gov/
geo/query/acc.cgi?acc=GSE11117) identified 40 matched
transcripts (additional file 5). Log-transformed expression
values of the 40 transcripts were used to classify the sam-
ples from GSE11117 into two subgroups using a correla-
tion, average-linkage hierarchical clustering R package.
Kaplan-Meier curves for these external samples using the
40 transcripts matched to our recurrence gene list demon-
strated statistically significant survival prediction (figure 3,
p < 0.0153)), with 21 and 20 samples in each group.
Integration of Genomic and Transcriptional Profiles
To determine whether integration of genomic and expres-
sion data added to the predictive value of these datasets
for histologic classification, we identified 34 genes whose
copy number and expression varied between AC and
SCC, 24 of which demonstrated concordant differences in
copy number and expression (table 4). Notably, 17 of 24
differentiating genes were located on chromosome 3q.
Associations with mutation status
Examination of transcriptional data from 1p, 1q, 6q,
11p, 11q and 12p (regions of genomic difference) identi-
fied 25 genes with concordant differences in copy num-
ber and expression between K-Ras mutant and wt
tumours (table 5). A number of genes demonstrated
reduced copy number and expression in KRAS mutant
tumours, including putative tumour suppressor genes
(FOXO3, EXTL2, PPP2R1B), negative regulators of the
receptor tyrosine kinase oncogenic pathways (PTPRK,
DGKZ, NCAM1), and negative regulators of Ras
(EPHB2). Several over-expressed genes located in
regions of amplification play roles in constitutive KRAS
activation (PTGS2/COX2), enhanced transactivation of
the EGFR (RGS2), enhanced invasive potential (ECM1),
and MAPK/ERK activation (PTGS2/COX2).
Associations with metastasis, tumour recurrence and
NSCLC-specific survival
Investigation of genomic and transcriptional data identi-
fied only 2 genes (ARFGEF1 and PENK)w h o s ec o p y
number and expression differentiated ‘metastatic’ from
Table 3 Details of genes over-expressed in K-Ras mutant tumours
Symbol Gene Name Cytoband P value Gene Function
ACOX2 Acyl-Coenzyme A oxidase 2, branched chain 3p14.3 4.9 E
-3 Lipid metabolism
ALDH2 Aldehyde dehydrogenase 2 family (mitochondrial) 12q24.2 9.8 E
-4 Alcohol metabolism
ALDH3B1 Aldehyde dehydrogenase 3 family, member B1 11q13 3.9 E
-3 Alcohol metabolism
AREG Amphiregulin (schwannoma-derived growth factor) 4q13-q21 1.4 E
-4 Autocrine growth factor family member
CD55 CD55 molecule, decay accelerating factor for
complement (Cromer blood group)
1q32 6.9 E
-4 Immune response, protection of cells from
complement mediated damage
CLDN10 Claudin 10 13q31-
q34
2.9 E
-3 Intercellular tight junctions
DGKD Diacylglycerol kinase, delta 130kDa 2q37.1 1.0 E
-3 Intercellular signalling, cell growth.
EGR1 Early growth response 1 5q31.1 2.5 E
-3 Transcriptional regulation of genes involved in
mitogenesis
MSLN Mesothelin 16p13.3 4.61 E
-5 Possible role in cell adhesion
MST1R Macrophage stimulating 1 receptor (c-met-related
tyrosine kinase)
3p21.3 4.5 E
-3 Cell motility, positive regulation of cell cycle
NPC2 Niemann-Pick disease, type C2 14q24.3 4.6 E
-4 Regulation of cholesterol transport and storage
NR4A1 Nuclear receptor subfamily 4, group A, member 1 12q13 6.2 E
-4 Transcription factor
PFDN1 Prefoldin subunit 1 5q31 1.5 E
-3 Cell cycle, transcription factor activity, protein folding
PTGS2 Prostaglandin-endoperoxide synthase 2 (cyclo-oxygenase
2)
1q25.2-
q25.3
3.1 E
-3 Prostaglandin biosynthesis
ST3GAL5 ST3 beta-galactoside alpha-2,3-sialyltransferase 5 2p11.2 1.4 E
-3 Cell differentiation, cell proliferation, signal
transduction.
TFPI2 Tissue factor pathway inhibitor 2 7q22 4.5 E
-4 Matrix remodelling, coagulation
UPP1 Uridine phosphorylase 1 7p12.3 1.0 E
-4 Nucleotide catabolism
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previously implicated in malignancy. Similarly, correla-
tion of transcriptional and genomic data identified only
3 genes with concordant differences in recurrence and
survival comparisons - SMARCA2, MINK and RECK.
Discussion
The clinical, demographic and pathologic characteristics
of this NSCLC cohort are consistent with the published
literature. The transcriptional and genomic profiles
identified in this study should therefore be generalisable
to other patients with early-stage NSCLC. The tumour
samples analysed demonstrated substantial genomic
instability, with comparisons between subgroups failing
to demonstrate any significant difference. Previous stu-
dies of copy number changes in NSCLC have found no
association between age, gender, histology, stage or
tumour grade and the degree of genomic instability
[19-21]. The absence of difference in the degree of
genomic abnormalities between KRAS mutant and wt
tumours is interesting, as both our transcriptional and
g e n o m i cd a t ai m p l ye n h a n c e da c t i v i t yo fg e n e si n v o l v e d
in chromosome structure and organisation in KRAS
mutant tumours. We recognise that there were a small
number of KRAS mutant tumours available for compari-
son and this may have limited our analysis.
Consistent with previously reported studies [9-16], the
major differences in copy number and gene expression
profiles between AC and SCC of the lung involved chro-
mosome 3q. The strong independent correlation with
amplification and over-expression at this locus suggests
a causal relationship in SCC for genes in this region
which warrant further investigation. These include
TP73L, a gene extensively implicated in SCC, whose
expression was most strongly correlated with the SCC
phenotype, and which has been previously reported to
be a putative oncogene [22-32]. While the role of TP73L
in squamous cell pathogenesis remains unclear, a recent
study of SiRNA mediated TP73L inhibition in SCC
resulted in reduced cell survival with maintenance of
squamous characteristics [28]. These results suggest that
TP73L is important in SCC cell survival. Other genes
previously shown to be over-expressed in SCC were
included in our differentiating list (CSTA [33,34],
FGFBP1), and warrant functional validation.
The differential copy number and expression levels
between AC and SCC of TNFSF10/TRAIL and ABCC5,
which have roles in apoptosis and chemoresistance respec-
tively, may have implications for treatment of NSCLC.
Recently published clinical data [35] suggest there are his-
totype-specific differences in response to systemic thera-
pies. Validation of the differential activity of the roles of
these genes and sensitivity to conventional and novel che-
motherapeutic agents may be an area for future research.
Published data on the relationship between TP53 muta-
tions and histotype in NSCLC is conflicting [36,37]. SCC
were associated with more frequent TP53 mutations than
AC in our dataset. Cigarette smoking is a causal factor for
both SCC phenotype and TP53 mutation [37]. However,
we also observed a correlation between 3q amplification
and TP53 mutations in AC samples. This suggests that the
apparent association between TP53 mutations and SCC
may be mediated by the relationship between TP53 muta-
tions and amplification of regions of 3q. We caution that
this study is underpowered to draw strong conclusions
regarding the role of TP53 in NSCLC pathogenesis.
Tumours possessing mutations of KRAS express genes
playing key roles in cell growth, chromosome organisation
Figure 3 Survival curves based on recurrence differential gene
list. A. Recurrence free survival curve for our dataset grouped by
recurrence differential gene list. B: Kaplan Meier survival curve for
external dataset GSE11117 using 40 transcripts matched to our
recurrence differential gene list to classify.
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amplification and over-expression of COX2 in KRAS
mutant tumours. KRAS mutant tumours did not demon-
strate mutations in EGFR consistent with previous reports
in both NSCLC and colon carcinoma which suggest that
KRAS mutations predict resistance to EGFR antagonists
[29,38-41]. Several reports link NCAM1 to Ras-dependent
activation of ERK MAPK’s [42,43]. Reduced copy number
and expression of NCAM1 in tumours bearing KRAS
mutations, as seen in our data, has not previously been
reported. Further research into a KRAS mutation profile
may yield simple and reliable immunohistochemical mar-
kers of KRAS mutation, thereby significantly reduce the
cost of determining KRAS status in clinical practice.
The gene expression profile observed in ‘metastatic’
tumours is consistent with a growing body of literature
implicating deregulated protein synthesis in the develop-
ment and metastatic potential of human cancers [44,45].
Increased mRNA translation is a critical downstream
function of many cancer related genes, and many gene pro-
ducts with roles in metastasis are not mutated but inappro-
priately expressed in malignant cells (e.g. VEGF, c-Myc, fos,
Her2Neu, PDGF) [18]. Opportunities for therapeutic inter-
vention currently in development include oncolytic viruses
that require deregulated protein translation for their replica-
tion [18], or agents that inhibit mTOR, an integral factor in
protein translation (eg. temsirolimus (CCI-779), everolimus
(RAD001) and deforolimus (AP23573)).
While the small number of recurrences and deaths
due to NSCLC in our tumour-set makes it difficult to
draw strong conclusions, transcriptional profiles linked
to tumour recurrence suggest KRAS pathway activation.
This may be due to a higher proportion of AC and LCC
vs. SCC in the ‘recurrent’ group. Other regions of copy
number change demonstrate genomic gains in the
region of c-Myc and losses in the region of p16 (INK4a,
CDNK2A) i nr e c u r r e n to rn o n - s u r v i v o rt u m o u r s ,s u p -
porting a prognostic association of the Myc:CDNK2A
Table 4 Details of genes located in regions of genomic difference with concordant differences in expression levels
between AC and SCC
Symbol Gene Name Cytoband Difference in
expression
(log2 SCC-AC)
P value
TP73L Tumour protein 73-like 3q28 2.94 1.69 E
-10
CSTA Cystatin A (Stefin A) 3q21 2.27 3.42 E
-8
ATP1B3 ATPase, Na+/K+ transporting, beta 3 polypeptide 3q23 1.46 1.06 E
-6
VNN2 Vanin 2 6q23-q24 1.34 1.00 E
-4
ABCC5 ATP-binding cassette, subfamily C, member 5 3q27 1.28 2.2 E
-4
UPK1B Uroplakin 1B 3q13.3-
q21
1.12 3.3 E
-3
RBP1 Retinol binding protein 1 3q23 1.12 1.98 E
-3
SGK Serum/glucocorticoid regulated kinase 6q23 1.06 1.3 E
-4
TNFSF10/
TRAIL
Tumour necrosis factor (ligand) superfamily, member 10/TNF-related apoptosis-inducing
ligand
3q26 1.05 1.7 E
-4
TNFAIP3 Tumour necrosis factor, alpha-induced protein 33 6q23 0.84 5.0 E
-4
PFN2 Profilin 2 3q25.1-
25.2
0.83 8.1 E
-3
PLOD2 Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 3q23-q24 0.80 6.7 E
-3
B3GNT5 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 5 3q28 0.80 2.8 E
-3
EIF4A2 Eukaryotic translation initiation factor 4A, isoform 2 3q28 0.66 4.1 E
-3
MAP3K4 Mitogen activated protein kinase kinase kinase 4 6q26 0.59 1.8 E
-3
PDCD10 Programmed cell death 10 3q26.1 0.58 2.9 E
-3
SEP1 5’-3’ exoribonuclease 1 3q25-
q26.1
0.54 8.2 E
-3
NCK1 NCK adaptor protein 3q21 0.52 7.3 E
-3
GPR126 G-protein coupled receptor 126 6q24.1 0.52 1.7 E
-3
LSAMP Limbic system-associated membrane protein 3q13.2-
q21
0.49 3.4 E
-3
DZIP3 Zinc finger DAZ interacting protein 3q13.13 0.45 4.9 E
-3
PIK3A2 Phosphoinositide-3-kinase, catalytic, alpha 3q26.3 0.44 9.2 E
-3
WASF-1 WAS protein family, member 1 6q21-q22 0.44 8.3 E
-3
CITED2/
MRG1
CBP/P300-interacting transactivator, with GLU/ASP rich carboxy-terminal domain 2/
Melanocyte specific gene 1 related gene 1
6q23.3 -0.63 8.0 E
-3
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SCC [46]. Specific genes linked to recurrence or survival
include SMARCA2 (implicated in the regulation of gene
expression cell cycle control and oncogenesis), MINK
(linked to the JNK MAP kinase pathway) [47] and
RECK, which has putative roles in the suppression of
tumour growth, invasion, angiogenesis and metastasis
[48]. KRAS mutation has been associated with reduced
expression of RECK in NSCLC [49], consistent with the
clinical observation of poor outcome in patients with
KRAS mutation bearing NSCLC. Activation of the Ras
pathway may reduce RECK expression and thereby
increase tumour recurrence. Importantly, our prognostic
gene signature was validated in an independent test set,
suggesting that these findings may eventually yield prog-
nostic markers in resected early-stage NSCLC to better
select patients for adjuvant treatments.
Conclusions
Several molecular alterations have been identified in
association with NSCLC histotype, KRAS mutation,
TP53 mutation, metastatic potential, disease recur-
rence and survival. Although the size of the current
study is small, our findings are in many cases consis-
tent with those of previous studies, and have been
validated in the case of the prognostic classifier in an
independent test set. In addition, several novel mole-
cular changes associated with clinically relevant end-
points have been demonstrated. It is hoped that these
results will contribute to identifying new predictive
markers and targets for novel therapies to improve
treatment selection and better outcomes for patients
with this deadly disease.
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Table 5 Details of genes with differential copy number and expression between K-Ras mutant and wild-type tumours
Symbol Gene name Cytoband Difference in
expression
(log2 mutant - wild
type)
P value
RGS2 Regulator of G-protein signaling 2, 24kDa 1q31 1.99 5.9 E
-3
NCAM1 Neural cell adhesion molecule 1 11 ( multiple
clusters)
-1.63 1.5 E
-3
CD55 CD55 molecule, decay accelerating factor for complement (Cromer blood group) 1q32 1.49 6.9 E
-4
PTGS2/
COX-2
Prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and
cyclooxygenase)/Cyclooxygenase-2
1q25.2-q25.3 1.32 3.1 E
-3
ECM1 Extracellular matrix protein 1 1q21 1.21 5.9 E
-3
EXTL2 Exostoses (multiple)-like 2 1p21 -1.08 4.2 E
-3
HIST2H2BE Histone cluster 2, H2be 1q21-q23 1.07 2.7 E
-3
H2AA Histone 2 1q21 0.95 1.2 E
-3
CHEK1 CHK1 checkpoint homolog (S. pombe) 11q24-q24 -0.94 6.1 E
-3
GPX7 Glutathione peroxidase 7 1p32 -0.88 5.6 E
-3
RWDD2A RWD domain containing 2A 6q14.2 -0.80 8.7 E
-4
HSF2 Heat shock transcription factor 2 6q22.31 -0.78 1.6 E
-3
BLR1 Burkitt lymphomas receptor 1, GTP binding protein (chemokine (CXC motif)
receptor 5)
11q23.3 -0.69 7.4 E
-3
MIZF MBD2-interacting zinc finger 11q23.3 -0.69 5.9 E
-3
KPNA5 Karyopherin alpha 5 (importin alpha 6) 6q22.2 -0.66 8.7 E
-3
LMO4 LIM domain only 4 1p22.3 -0.66 3.2 E
-3
MUTYH MutY homolog (E. coli) 1p34.3-p32.1 -0.65 4.9 E
-4
REV3L REV3-like, catalytic subunit of DNA polymerase zeta (yeast) 6q21 -0.65 8.8 E
-3
EPHB2 Ephrin B2 1p36.1-p35 -0.64 6.7 E
-3
DGKZ Diacylglycerol kinase, zeta 104kDa 11p11.2 -0.64 9.2 E
-3
TSPYL4 TSPY-like 4 6q22.1 -0.63 1.6 E
-3
DBT Dihydrolipoamide branched chain transacylase E2 1p31 -0.58 5.8 E
-3
FOXO3 Forkhead box O3 6q21 -0.53 5.7 E
-3
PPP2R1B Protein phosphatase 2, regulatory subunit A, beta isoform 11q23.2 -0.51 2.7 E
-3
PTPRK Protein tyrosine phosphatase, receptor type, kappa 6q22.2-q22.3 -0.08 4.3 E
-4
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